Overview

Levetiracetam 1000 mg Under Non-Fasting Conditions

Status:
Completed
Trial end date:
2007-01-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to compare the rate and extent of absorption of an investigational formulation of levetiracetam 1000 mg tablet to an equivalent oral dose of the commercially available reference product under fed conditions.
Phase:
Phase 1
Details
Lead Sponsor:
Teva Pharmaceuticals USA
Treatments:
Etiracetam
Levetiracetam
Piracetam